3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
16
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasm Metastasis
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Solid Tumors Refractory to Standard Therapy
1
Solid Tumors
1
Solid Tumor, Adult
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Kidney Neoplasms
1
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
1
Hereditary Sensory and Autonomic Neuropathies
1
HER2-positive Breast Cancer
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Interventions
palbociclib
1
aumolertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
×
palbociclib
×
Clear all
NCT06947811
2025-06-04
APEAK
Sun Yat-sen University
Phase 1/2
Recruiting
71 enrolled